EGFR and non-small cell lung carcinoma: Another study showed the upregulation expression of PD-L1 in NSCLC as a result of an EGFR mutation and ALK rearrangement via common downstream signalling pathways mediated by PI3K-AKT and by MEK-ERK18, implicating driver mutations in the regulation of the expression of immunosuppressive molecules.